[1] Hildesheim A WS, DeVeyra E, De Guzman MF, et al. Herbal Medicine Use, Epstein-Barr Virus and Risk of Nasopharyngeal Carcinoma. Cancer Res, 1992; 52, 3048-51.
[2] Brooks L YQ, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells:coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol, 1992; 66, 2689-97. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_241023
[3] Lee SP, Tierney RJ, Thomas WA, et al. Conserved CTL epitopes within EBV latent membrane protein 2:a potential target for CTL-based tumor therapy. J Immunol, 1997; 158, 3325-34.
[4] Tsang CW, Lin X, Gudgeon NH, et al. CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes. J Virol, 2006; 80, 8263-6. doi:  10.1128/JVI.00400-06
[5] Hui EP, Taylor GS, Jia H, et al. Phase Ⅰ trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Res, 2013; 73, 1676-88. doi:  10.1158/0008-5472.CAN-12-2448
[6] Smith C, Tsang J, Beagley L, et al. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res, 2012; 72, 1116-25. doi:  10.1158/0008-5472.CAN-11-3399
[7] Taylor GS, Haigh TA, Gudgeon NH, et al. Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct:potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol, 2004; 78, 768-78. doi:  10.1128/JVI.78.2.768-778.2004
[8] Wang Z, Zhou L, Du HJ, et al. Immunological effects of rAd-LMP2 in different time point. Guide of China Medicine, 2010; 18, 78-9. (In Chinese)
[9] Zhang LX, Li HX, Wang Z, et al. Preliminary study on the immunological effect with MVA vaccine of epstein-Barr virus·LMP2 gene. Chin J Exp Clin Virol, 2014; 28, 20-2. (In Chinese)
[10] Shuangqing Y, Xia F, Tsugumine S, et al. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B. Vaccine, 2008; 26, 6124-31. doi:  10.1016/j.vaccine.2008.09.017